Sharma Jyoti, Deb Barnali, George Irene A, Kapil Shruthi, Coral Karunakaran, Kakkar Nandita, Pattanaik Smita, Mandal Arup Kumar, Mavuduru Ravimohan S, Kumar Prashant
Institute of Bioinformatics, International Technology Park, Bangalore, India.
Manipal Academy of Higher Education (MAHE), Manipal, India.
Front Oncol. 2019 May 29;9:435. doi: 10.3389/fonc.2019.00435. eCollection 2019.
Urothelial carcinoma is the most common malignancy of the bladder and is primarily considered as a disease of the elderly. Studies that address bladder tumor occurrence in young age groups are rare. A 19-year-old male presented with a gross total painless hematuria. A histology after biopsy revealed a high-grade transitional cell carcinoma with lymph node metastasis. The patient succumbed to the disease on day 72 of the treatment. Here, we used whole-exome sequencing of a paired tumor-normal sample to identify the somatic mutations and the possible targets of treatment. We predicted eight potential driver mutations ( p.V157L, c.1498+1G>T, p.L1127P, p.S713C, p.P2212A, p.G556V, p.Q814K, and p.S1078). In addition, we predicted deleterious mutations in genes involved in the ion channels ( p.E1581K, p.P71T, p.G404W, p.A1096T, p.G16V, p.E874K, p.R131S, p.A296D, and p.R558H). Most likely, mutations in genes involved in ion channels may be responsible for the aggressive behavior of a tumor. Ion channels are the second largest class of drug targets, and may thus serve as a putative potential therapeutic target in advanced stage urothelial carcinoma.
尿路上皮癌是膀胱最常见的恶性肿瘤,主要被认为是一种老年疾病。针对年轻年龄组膀胱肿瘤发生情况的研究很少。一名19岁男性出现全程无痛性血尿。活检后的组织学检查显示为高级别移行细胞癌伴淋巴结转移。患者在治疗第72天死于该疾病。在此,我们对配对的肿瘤-正常样本进行全外显子组测序,以鉴定体细胞突变和可能的治疗靶点。我们预测了8个潜在的驱动突变(p.V157L、c.1498+1G>T、p.L1127P、p.S713C、p.P2212A、p.G556V、p.Q814K和p.S1078)。此外,我们预测了参与离子通道的基因中的有害突变(p.E1581K、p.P71T、p.G404W、p.A1096T、p.G16V、p.E874K、p.R131S、p.A296D和p.R558H)。参与离子通道的基因中的突变很可能是肿瘤侵袭性的原因。离子通道是第二大类药物靶点,因此可能作为晚期尿路上皮癌的一个假定潜在治疗靶点。